Leukocyte Rich- PRP injection: Autologous Leukocyte Rich-Platelet Rich Plasma will be injected in the hip joint
Leukocyte Poor- PRP injection: Autologous Leukocyte Poor-Platelet Rich Plasma will be injected in the hip joint
Study summary
The aim of the study is to compare the efficacy up to 12 months of two different types of PRP (PRP with leukocytes vs PRP depleted of leukocytes) in the echo-guided infiltrative treatment of hip OA by including 230 patients in the study and evaluating them through subjective (using the WOMAC score as the primary outcome) and objective clinical scores.
Eligibility
Sex
ALL
Min age
35 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Signs and symptoms of hip OA (pain intensity of at least 4 points and not more than 8 of VAS pain - 0-10 scale in the previous week);
* Radiographic signs of hip OA (Grade 1-2 according to Tonnis classification) or MRI signs (chondropathy or minimal labrum degeneration without acute lesions) even if Grade 0.
* Unilateral involvement; Hemoglobin \> 11 g/dl;
* Platelet count \> 150,000 plt/mm3 (Recently performed CBC examination);
* Negative serological tests for HBsAg, HCV Ab, HIV-1-2 Ab
* No clinically significant electrocardiographic changes (Recently performed ECG).
* Ability and consent of patients to actively participate in clinical follow-up;- Signature of informed consent.
Exclusion Criteria:
* Patients unable to express consent;
* Patients undergoing infiltration of other substance in the previous 6 months;
* Patients undergoing lower limb surgery to be treated in the previous 12 months;
* Patients with malignant neoplasms;
* Patients with rheumatic diseases;- Patients with uncontrolled diabetes;-Patients with hematological diseases (coagulopathies);
* Patients on anticoagulant-antiaggregant therapy that cannot be discontinued for at least 3 days prior to blood collection;
* Patients with uncontrolled thyroid metabolic disorders;
* Patients abusing alcoholic beverages, drugs or medications;
* Body Mass Index \> 30;
* Patients who have taken NSAIDs in the 3 days prior to blood draw;
* Patients with cardiovascular disease for whom 300 ml blood draw would be contraindicated;
* Patients with recently performed CBC examination with Hb\< 11 g/dl and Platelet values \< 150,000 plt/mm3.
* Positive serological tests for HBsAg, HCV Ab, HIV-1-2 Ab
* Pregnant and/or fertile women.
* Pain intensity less than 4 points or greater than 8 in accordance with the VAS scale.
* Patients with other hip pathologies: acetabular protrusion, concentric migration of the femoral head, presence of excessive deformity resulting from acetabular or femoral head dysplasia, collapse deformity, and deformed femoral head sequelae of Perthes disease or osteonecrosis of the femoral head.
* Previous extensive surgery of the reference joint (osteotomy around the hip, open or arthroscopic osteochondroplasty for femoro-acetabular conflict).
Primary outcome measure(s)
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) — 6 months follow-up It's a standardized and widely used questionnaire to assess the condition of patients with osteoarthritis of the knee and includes assessment of pain, stiffness, and physical function of the joints. It can be administered to the patient.
It measures 5 items for pain (range 0-20), two for stiffness (range 0-8), and 17 for functional limitation (range 0-68) that mainly relate to activities of daily living (e.g., getting up from a sitting position, bending over, going up and down stairs etc.); The score is then normalized on a 0-100 scale. Higher values indicate a worse outcome
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
